Loading...
•
Mar 31, 2024
Dynavax Q1 2024 Earnings Report
Reported financial results and provided a business update for the quarter ended March 31, 2024.
Key Takeaways
Dynavax reported a 10% year-over-year growth in HEPLISAV-B net product revenue, reaching $47.8 million in Q1 2024. The company is reaffirming its full-year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million. The U.S. FDA cleared the IND application to initiate a Phase 1/2 trial of the Z-1018 shingles program.
HEPLISAV-B vaccine net product revenue grew 10% year-over-year to $47.8 million in the first quarter of 2024.
Dynavax is reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million.
The U.S. FDA cleared the IND application to initiate a Phase 1/2 trial of Z-1018 shingles program.
HEPLISAV-B total estimated market share in the U.S. increased to approximately 41%.
Revenue by Segment
Forward Guidance
Dynavax is reaffirming the following full year 2024 financial guidance, based on the Company’s current operating plan:
Positive Outlook
- HEPLISAV-B net product revenue between approximately $265 - $280 million, including approximately $3 million in ex-U.S. sales through commercialization partnership in Germany
- HEPLISAV-B gross margin of approximately 80%
- Research and development expenses between approximately $60 - $75 million
- Selling, general and administrative expenses between approximately $160 - $180 million
- Expect cash, cash equivalents and marketable securities to be higher as of December 31, 2024, compared to December 31, 2023
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...